Colorectal Cancer

>

Latest News

Exercise-Based Regimen Shows Efficacy Promise in CRC
Exercise-Based Regimen Shows Efficacy Promise in CRC

June 30th 2025

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

June 28th 2025

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

June 23rd 2025

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases
Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

June 20th 2025

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

June 17th 2025

Video Series
Video Interviews
Podcasts
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
New treatment updates could help find more patient subtypes to target and treat in the world of CRC.
Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.
Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.

More News